ConductScience.org, home

Paper3350837

Role of recombinant interferon alpha 2 and cimetidine in patients with advanced malignant melanoma.

Mughal TI and 3 others. J Cancer Res Clin Oncol, 1988. Cited by 16 papers, by iCite.

Cite this record

ConductScience Library. Role of recombinant interferon alpha 2 and cimetidine in patients with advanced malignant melanoma. Papers, record 3350837. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3350837

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Role of recombinant interferon alpha 2 and cimetidine in patients with advanced malignant melanoma.
PubMed
Journal
J Cancer Res Clin Oncol
PubMed
Year
1988
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
16
iCite
Relative citation ratio, by iCite
0.61
iCite
Revised in PubMed
2025-07-19
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Mughal TIT I
2Robinson WAW A
3Thomas MRM R
4Spiegel RR

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
CimetidineMajor topic
Interferon Type IMajor topic
MelanomaMajor topic
Female
Male
Recombinant Proteins

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
RR-51NCRR NIH HHSUnited StatesPubMed

Source PubMed

Download CSV of grants

References10

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
17459811Reporting results of cancer treatment.Cancer1981https://conductscience.org/library/papers/7459811PubMed
26663321Immunological effects of recombinant interferon-alpha 2 in cancer patients.J Biol Response Mod1983https://conductscience.org/library/papers/6663321PubMed
36176159Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients.Ann Intern Med1982https://conductscience.org/library/papers/6176159PubMed
47121522Human leukocyte interferon and cimetidine for metastatic melanoma.N Engl J Med1982https://conductscience.org/library/papers/7121522PubMed
586136Antitumour effect of cimetidine.Lancet1979https://conductscience.org/library/papers/86136PubMed
626297790Pillars Article: Virus Interference. I. The Interferon. Proc R Soc Lond B Biol Sci. 1957. 147: 258-267.J Immunol2015https://conductscience.org/library/papers/26297790PubMed
76174742Clinical and immunologic effects of recombinant leukocyte A interferon in eight patients with advanced cancer.JAMA1982https://conductscience.org/library/papers/6174742PubMed
86110864Successful tumour immunotherapy with cimetidine in mice.Lancet1981https://conductscience.org/library/papers/6110864PubMed
93804370Treatment of metastatic malignant melanoma with recombinant interferon alpha 2.Immunobiology1986https://conductscience.org/library/papers/3804370PubMed
106323641Interferons in the treatment of human cancer.J Clin Oncol1984https://conductscience.org/library/papers/6323641PubMed

Download CSV of references

Cited by6

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 16 citations.

PMIDTitleJournalYearIn PapersSource
39850890Extracellular matrix shapes cancer stem cell behavior in breast cancer: a mini review.Front Immunol2024https://conductscience.org/library/papers/39850890PubMed
9306593Anorectal malignant melanoma: report of a case.Surg Today1997https://conductscience.org/library/papers/9306593PubMed
8542245Experience with interferon alpha 2b combined with dacarbazine in the treatment of metastatic malignant melanoma.Med Oncol1995https://conductscience.org/library/papers/8542245PubMed
8097142Effects of histamine type-2 receptor antagonists on indomethacin and IL-2 immunotherapy of metastasis.Clin Exp Metastasis1993https://conductscience.org/library/papers/8097142PubMed
7681371Interferon-alpha in malignant and viral diseases. A review.Drugs1993https://conductscience.org/library/papers/7681371PubMed
2573506Rational use of antihistamines in allergic dermatological conditions.Drugs1989https://conductscience.org/library/papers/2573506PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
IFNA23440PubTator's text mininghttps://conductscience.org/library/genes/3440

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/3350837

GET https://conductscience.org/api/papers/v1/3350837/authors